PCBN has established and where appropriate implemented policies to ensure:

High ethical and privacy standards to protect the participants from whom PCBN biospecimens are obtained.

  • All network sites of the PCBN operate with the review and approval of their local Institutional Review Board (IRB).
  • Donor identities or identifying information are not provided to investigators; all biospecimens disbursed are anonymized or de-identified.
  • As custodians of the biospecimen and data collection, appropriate material transfer procedures are followed and documented when material is disbursed.

Optimal preservation procedures to maintain architecture and molecular integrity of PCBN biospecimens.

  • SOPs developed and implemented constitute best practices.
  • Evaluate the influence of pre-analytical variation on biomarker assay results.
  • Characterize critical parameters in the biospecimen "life cycle" that influence the molecular integrity of research tissues.

Fair and equitable access to PCBN biospecimens by academic and private industry scientists.

  • PCBN is an open access biorepository.
  • PCBN activity is transparent; standard operating procedures and tissue access policy are available online.

Research conducted using materials obtained through PCBN contributes to improving cancer outcomes.

  • All requests for PCBN material are subject to review by Specimen Request Review Committee. See Review Criteria .
  • The Prostate Cancer Biorepository Network (PCBN) should be acknowledged as per the following statement: "This work is supported by the Department of Defense Prostate Cancer Research Program, Award No W81XWH-18-2-0013, W81XWH-18-2-0015, W81XWH-18-2-0016, W81XWH-18-2-0017, W81XWH-18-2-0018 and W81XWH-18-2-0019 Prostate Cancer Biorepository Network (PCBN)". This is required as an outcome measure of the productivity of the PCBN.
  • Unused samples should be returned to the PCBN.
  • The PCBN should be notified of project completion and, once the results have been approved for publication, individual biomarker results should be deposited in the PCBN database. This will allow the data value of each specimen to increase dynamically as research results on the same patient specimens cumulate over time, which will benefit the applicant, PCBN and the prostate cancer research community.
  • Feedback regarding the quality of the samples or any issues with the samples would be appreciated.